Note: Descriptions are shown in the official language in which they were submitted.
WW-0049
Background
The use of topical steroids is known to result in
certain unwanted side effects, among them cutaneous
atrophy, or diminution of the epidermis and dermis, at
or near the cite of steroid application. Such atrophy
is generally characterized by thinning, shininess,
increased transparency and telangiectasia.
There are many regimens and a variety of reasons
for treating conditions with steroids and/or
hydroxyacid-based reagents. Applicants know of no
references to the use of hydroxyacid salts, e.g.
lactates, to ameliorate the adverse effects of topical
steroid usage.
U.S. 4,105,783 describes the treatment of dry
skin, or "ichthyosis", using the acid, amide or
ammonium salt of an a- or ~-hydroxyacid. Lactic acid,
or a-hydroxypropionic acid, is one of the a-hydroxy-
acids mentioned.
U.S. 4,246,261 shows topical compositions
containing steroids in which the efficacy of the
steroid used is enhanced via the use of salts of
lactic or other a-hydroxyacids, derived using various
bases.
U.S. 4,363,815 deals with compositions for
treating skin infla~.-;ation or disturbed
keratinization. Hydroxyacid/base reaction products
are disclosed as useful therein.
U.S. 4,485,091 refers to skin creams which
contain sodium and potassium lactates as buffers.
E.P.O. Publication 0273202 discloses combinations
of therapeutic agents with hydroxycarboxylic acids or
salts thereof. At page 16, an ointment containing
_2_
7
W~~7-0049
betamethasone dipropionate and 2-methyl-lactic acid is
recited.
Lac-Hydrin~ lotion, a product of Westwood Squibb
Pharmaceuticals, Inc. (Buffalo, N.Y.), is described on
page 2285 of the 1990 Physician's Desk Reference as
12% lactic acid, neutralized with ammonium hydroxide
(i.e., ammonium lactate). The lotion has a pH of 4.5-
5.5 and is disclosed as useful in treating dry, scaly
skin (xerosis), ichthyosis vulgaris and the itching
associated with these conditions.
The Invention
It has been discovered that certain salts of
alpha-hydroxyacids thicken the skin, specifically the
viable epidermis, and increase certain dermal
components (ground substance) so that the atrophic
effects of topical steroid usage are lessened.
In a preferred embodiment, a 0.05% clobetasol 17-
propionate cream was applied to the skin of a group of
subjects every morning for four weeks. Buffered
ammonium lactate (12% Lac-Hydrin0) was applied eight
hours after each steroid application. Other groups
received applications of only steroid or ammonium
lactate salt once Gaily.
Skin treated with only steroid showed a 51%
decrease in thickness, while that treated with steroid
followed by a:~.~o.~.~u:n lactate showed only a 35%
decrease in thickness.
Objects of The Invention
It is one object of the invention to provide
compositions and processes for treating skin atrophy.
-3-
2a~~ i2~
It is another object to provide compositions and
processes for thickening skin.
It is yet another object of the invention to
increase the ground substance in the viable epidermis
of subjects and, thereby, ameliorate the effects of
biological aging and/or damage by chemical agents or
light.
The compositions and the processes of the
invention employ useful quantities of salts of certain
a-hydroxyacids. Optionally, they may also employ one
or more steroid components.
Thus, the present invention provides a composition
for treating the skin atrophy associated with topical
steroid use which composition contains an effective
amount of a salt of CZ_~ alpha-hydroxyacid. In another
aspect the invention provides a process for treating
skin atrophy associated with topical steroid use which
comprises the step of contacting the affected skin with
a composition containing an effective amount of a salt
of a C2_7 alpha-hydroxyacid. In other aspects the
invention provides processes for thickening skin,
and/or process for increasing the ground substance in
the viable epidermis of a subject, comprising
contacting same with a composition containing an
effective amount of a salt of a CZ_~ alpha-hydroxy acid.
In another aspect the invention provides the
use of a composition containing an effective amount of
a salt of CZ_7 alpha-hydroxy acid for treating skin
atrophy associated with topical steroid use.
In another aspect the invention provides the
use of an effective amount of a salt of C2_~ alpha-
hydroxyacid, for the preparation of a medicament for
skin atrophy associated with topical steroid use.
4
2G ~3 /~ ~
Advantages
The compositions and methods of the invention have
several advantages over other dermatological systems
now in use.
One principal advantage is the lessening of the
cutaneous atrophy usually associated with the topical
use of steroids and some other medicaments.
Another is the fact that, while lessening one or
more of the side effects of such drugs as steroids, the
salts of the invention do not alter the efficacy of
these drugs in any way. Accordingly, there is no
"masking" or "dilution" of the steroid used.
Still another advantage is the compatibility of
the salts of the invention with steroids and other
topical therapeutic agents. The salts may be simply
blended into formulations containing the steroid.
Thus, the salts of the invention may be
administered either along with a steroid or other
topical drug or in a separate step, that is, either
concomitant therewith, previous thereto or subsequent
thereto. It has been found that using the salt after
4a
~,
'~., i~:,
J
Zv'4v'-OC49
use of the steroid can lessen the atrophic effects of
the steroid without altering its beneficial effects.
The salts of the invention can also be used in
any system in which temporary thickening-of the
epidermis is desired. For example, persons with known
sensitivities to certain agents, e.g. sunlight or
certain. hair or makeup preparations, and those whose
skin has become biologically aged can have their skin
toughened or made less sensitive by using the systems
of the invention before exposing their skin to
harmful agent(s).
These and other advantages of the invention will
be apparent after a consideration of the following
description and claims.
Describtion of the Invention
Drawings
Figures la-ld are light micrographs cf the
epidermis and dermis of a subject treated as follows
for four weeks.
la. Control
lb. 12o ammonium lactate treatment
lc. clobetasol propionate treatment
ld. 12% ammonium lactate following clebetasol
propionate treatment.
The amount of agent applied in each of testings
lb through ld was 0.2 ml.
The invention concerns compositions and processes
for thickening skin and for lessening the atrophic
effects of topical steroid usage.
Unless stated other~aise, all percentages
mentioned herein are weight percentages, based on
total composition weight.
-5-
Wfr7- 0 0 4 9
All publications referred to herein are hereby
incorporated by reference.
The compositions and processes of the invention
employ certain salts, optional steroids and, if
desired, various additives conventionally used in
topical formulations.
Salts
Useful salts are generally obtained via the
reaction of suitable bases with a-hydroxyacids of
formula I:
R-CH-COOH (I)
OH
wherein R is H or a C1_5 hydrocarbon group.
Preferably R is an alkyl group, such as a C1_3
alkyl group, with methyl and ethyl groups being highly
preferred. R is most preferably a methyl group, so
that salts derived from a-hydroxypropionic acid, or
lactic acid, are most preferred. Mixtures of acids
may be used.
The bases used to produce the salts of the
invention contain either nitrogen atoms, present as
ammonium ions or amine nitrogen, or metal ions.
Ammonium-containing species to be used can be,
for example, NH~OH, Fid(R'-)30H, or N(R~)40H, in which
each R1 is independently a C1_~ alkyl or aryl group.
Mixtures are operable. Ammonium hydroxide is a
preferred reactant.
Amines are another group of nitrogen-containing
reactants which may be used to make the salts of the
invention. Useful amines include organic primary,
secondary and tertiary amines which contain 1-3
-6-
WW-009
nitrogen atoms. The organic groups of these amines
are generally C~_8 alkyl or aryl groups, optionally
substituted with one more hydroxyl groups. Preferred
amines include alkanolamines, diamines, dialkylamines,
dialkanolamines, alkylalkanolamines, trialkylamines,
trialkanolamines, dialkyl- or alkanol-amines and alkyl
diethanolamines.
Alternatively, the salts of the invention can be
produced using metal ion-containing reagents.
Preferred metal ion-containing bases are those which
result in salts containing atoms of Na, K, Ca, Mg, or
Li. Typically the metal ion reactants are hydroxides.
Mixtures are contemplated.
The salts of the invention are produced via
conventional acid/base reactions, such as that
involving ammonium hydroxide and lactic acid.
Conventio:~al reaction vessels are used. Reaction
temperatures to be used depend upon the particular
reactants and the other reaction conditions selected.
One useful source of amr.,onium lactate is the 120
lotion sold as "Lac-Hydrin0" by Westwood Squibb
Pharmaceutical Co.
The salts of the invention will be present, when
used alone in formulations, in an amount ranging from
about 1% to about 53%, preferably about 2% to about
38 0 .
It should be noted that, while the disclosure
refers to salts of bases and a-hydroxyacids, it is
contemplated that mere mixtures ef these types of
reagents be used. Accordingly, mixtures of acids and
bases, such as those disclosed in U.S. 4,105,783 are
also operable in the invention.
_7_
WW-0049
Steroids
The steroids useful in the invention are any of a
wide variety of materials generally characterized as
corticosteroids.
The steroids may be used in their base form, or
they may be used as the esters, amides, ethers, etc.
which are conventionally used in pharmaceutical
preparations.
Steroids are generally characterized as being of
high, medium, or low potency. Clobetasol propionate,
a high potency steroid, has been found to be very
useful in the invention. However, low and moderate
potency steroids, e.g., by drocastisone and beta-
methasone-17-valerate, respectively, are believed to
be useful.
Among the preferred steroidal agents to be used
in the invention are the corticosteroids
conventionally employed in topical dermatological
formulations. Thus, useful agents include those
listed below:
Alclometasone dipropionate
Betamethasone
Betamethasone benzoate
Betamethasone dipropionate
Betamethasone valerate
Clobetasol propionate
Clobetasol valerate
Deprodone propionate
Desflurotriamcinolone
Dexamethasone
Dexamethasone acetate
Dexamethasone sodium phosphate
Diflorasone diacetate
Flumethasone valerate
Fluocinolone acetamide
Halobetasol propionate and others in
U.S. 4,619,921
Hydrocortisone
Hydrocortisone acetate
_g_
WW-0049
Hydrocortisone valerate
Mometasone furoate
Triamcinolone acetonide
Mixtures of one or more of the compounds
mentioned above are operable.
In addition, the use of other conventional
steroidal agents such as the free agents and other
esters and amides of the agents listed above, e.g.,
dexamethasone valerate, whether used alone or in
mixtures, are contemplated.
Salt/Steroid Mixtures
While the salts of the invention can be topically
applied separately from the steroid(s), they may also
be mixed with them, i.e., in the same formulation.
When salts and steroids are used in the same
formulation, the concentration of salt will be from
2 0 about 1 o to about :J 3 0 , pr ef erably about 2 % to about
38%. The concentration of steroid will be from about
0.0005% to about 3.0%, preferably about 0.01% to about
l.Oo.
Additives
Since the fcr~ulations of the invention are to be
used topically, i.e. by application to a..~,d absorption
into the skin of the subject to be treated, they will
usually contain certain additional ingredients which
render them suitable for such use. Thus, a variety of
conventional ingredients, such as emulsifiers,
diluents, fillers, preservatives, moisturizers,
thickeners, colorants, perfumes, buffers, etc. can be
_g_
WW-0049
employed in these compositions in amounts of~from
about 0.05 to about 99.5%.
The topical formulation of the invention are
generally employed as creams, lotions, ointments, gels
or sprays. Other liquid or semi-solid forms are
contemplated. Additives appropriate to use in these
forms are also contemplated.
Other therapeutic agents may also be used in the
formulations of the invention. Thus, antifungal
agents (e. g., imidazoles), anesthetics (e. g., methyl
solicylate), humectants (e. g., glycerin),
antibacterials (e.g., erythromycin, clindamycin) and
the like may be used. It should be noted that any
additional therapeutic agents should be of such
types) and in such amounts) that their presence does
not interfere with the function of the salt or the
salt/steroid combination in the formulation.
Generally, minor amounts of such additional
therapeutic agents, i.e., about 10% or less,
preferably about 0.001% to about 5%, can be used.
While the pH of the systems described herein is
not critical, it is generally the case that
compositions whose final pH values lie between about
3.0 and about 7.5, and preferably about 4.0 and about
6.0, are operable. These pH ranges assure maximum
beneficial properties for the. salt in the
formulations.
Depending upon the presence of a steroid or ether
therapeutic agent in the formulation, the use of
slightly lower pH's may be beneficial.
-10-
.- WW-0049
Administration
Generally, the topical formulations of the
invention are administered from about one to about
three times, and preferably one to two times, per day.
When the salt is not applied along with the
steroid, it can be applied from 4 to 24 hours, and
preferably about 8 hours, before or after the
administration of the steroid. It is preferred that
the salt be applied after the steroid has been
applied.
When the salt-containing formulation is to be
used to temporarily thicken the subject's skin, the
use of the formulation one to four times daily is
suggested.
The individual needs of the subject and the
desires of the physician may call for deviations from
the routines suggested above.
The term "subject" is intended to mean any mammal
upon whose skin or other dermal surface the
compositions of the invention can be applied. It is
generally preferred that the subject to be treated in
accordance with the invention be a human patient.
Also, the salt-containing formulations of the
invention can be employed to ameliorate the
dermatological effects of topical steroid use for
subjects of pre-adult age.
Discussion of Drawings
The drawings show the sequence of epidermal and
dermal changes in the same individual after treatment
-11-
~~~~i~~
w-~a-oo~9
with nothing (a), 12% ammonium lactate (b), clobetasol
propionate (c) and the combination ammonium lactate
and clobetasol propionate (d) for four weeks in an
open fashion.
a. Control. Normal epidermis (E) showing well
developed rete ridges (rr) which results in an
undulating dermal/~epidermal interface.. Horny layer
(H) displays typical "basket weave" pattern usually
associated with paraffin fixed specimens. Papillary
dermis (PD) contains prominent microvasculature (mv)
as well as a moderate amount of glycosaminoglycans
(arrows). Magnification = 200X
b. 12% ammonium lactate. Viable epidermis (E)
is thicker than control and shows distinct regions of
blue coloration (*) indicative of the presence of
glycosaminoglycans. Horny layer (H) maintains the
"basket weave" pattern seen in control specimens.
Papillary dermis (PD) shows a striking increase in
glycosaminoglycan deposition. mv, microvasculature.
c. clobetasol propionate. Viable epidermis (E)
is markedly thinner than control, and the horny layer
(H) is virtually ablated. Papillary dermis (PD)
appears compressed and there is a striking diminution
in glycosamincglycans (arrows) and vascular (mv)
profiles.
d. combination treatment with 12s ammonium
lactate and clobetasol propionate. Viable epidermis
(E) appears si:~ilar in thickness to control specimens,
and horny layer (H) still retains the "basket weave"
appearance. Papillary dermis (PD) shows striking
amounds of glycosaminoglycans (arrrsws) as well as
numerous microvascular (mv) profiles.
In general, viable epidermis (E) is thicker and
granular layer (arrows) is more prominent after
-12-
f
WW-0049
ammonium lactate treatment. Note preservation of
"basket weave" horny layer (H) after ammonium lactate
treatment. No increase in cellularity is seen in the
dermis (D) after ammonium lactate treatment.
*,microvasculature X 150.
Examples
The following examples serve to illustrate the
invention.
Example I: Effects of Lac-Hvdrin~ cn the
Bioavailability of a Potent Topical Corticosteroid
Experimental Design
A total of 10 healthy adult volunteers between
the ages of 19 and 60 years participated in this
investigation. There were 5 females and 5 males.
After washing the forearms with a bland soap
(Ivory~) and patting dry with a soft towel, three
circular sites, each measuring 1.2 cm in diameter,
were,outlined in ink on the volar aspect of the
forearm. Twenty microliters of each of the test
products (0.050 Temovate~ (clobetasol propionate)
ointment, Lac-Hydrin~ 12% lotion, and the combination
together) were delivered to a designated test site.
On the morning of the first study date, two
designated sites on each forearm received Lac-Hydrin~.
The subjects returned 6-8 hours later on the same day
and received Temovate~ ointment to a third site and to
one of the sites previously treated with Lac-Hydrin~.
One forearm was then occluded with plastic Saran
Wraps while the sites on the opposite arm were covered
with circular plastic chambers in which a 1 cm hole
-13-
WPI-0049
was punched out from the center. The chambers were
applied over each site and taped at the edges to
prevent clothing from rubbing against or touching the
skin surface. Sixteen (16) hours after the p.m.
application the protective chambers and Saran Wrap~
were removed and both forearms were washed again with
soap and water and blotted dry with a towel.
Clinical Observations
The degree of blanching at each test site was
graded 30 minutes after the products were washed from
the skin, i.e., 16-17 hours after application, and
again 24 hours after the last application of the test
products.
Grading of the degree of blanching was done in a
blind fashion using standardized lighting by the
investigator who was unaware of the test product
assignment and who did not participate in the
application of the test products. The following
grading scale was used:
0 = no vasoconstriction
1 = minimal visible blanching
2 = definite blanching with well-defined borders
3 = more intense blanching
4 = intense blanching, spreading beycnd the
application site.
Results
The individual and total vasoconstriction scores
for each test product at both time points (16 and 24
hours) are listed in Tables 1 and 2. The degree of
blanching for both open and occluded applications
ranged from 0-3. The mean vasoconstriction scores for
both forearms were similar for both 16 anti 24 hour
time-points for all test sites. No blanching was
-14-
WW-0049
observed in sites treated~with Lac-Hydrin~ alone.
Prior treatment with Lac-Hydrin~ did not appear to
influence the vasoconstriction by clobetasol
propionate ointment in either the open (Table 1) or
occluded (Table 2) sites.
The individual scores for both forearms were
compared using paired t-tests and no significant
differences were found in the degree of blanching by
prior treatment with Lac-Hydrin~. Thus, the treatment
of the forearm with Lac-Hydrin~ prior to application
of a potent topical corticosteroid does not effect the
bioavailability of the corticosteroid.
Table 1. BLANCHING SITES
SCORES
FOR
OPEN
Lac-F?ydrin~12% Temovate~
Lac- Hydrin~ Lotion & Temovate~Ointment
Subject 12% Lotion Ointment 0.05% 0.05%
NumberArm 16 . 24 16 ~?rs. 24 Ers. 16 24
Firs ~:rs. Hrs. Y.rs.
1 R 0 0 2 2 2 2
2 L 0 0 1 2 2 2
3 L 0 0 2 3 2 3
4 R 0 0 3 1 3 2
5 R 0 0 2 2 2 2
6 R 0 C 2 2 2 2
7 R 0 0 1 1 1 1
8 L 0 0 1 2 1 2
9 R 0 0 2 3 2 3
10 L 0 0 3 2 3 2
Total
Score: 0 0 19 20 20 21
-15-
W'4-0049
Table 2. BLANCFINGSCORES FOR OCCLUDED
SITES
Lac-Hydrin~l2$ Temovate~
Lac-Hydrin~ Lotion & Temovate~Ointment
Subject 12$ Lotion Ointment 0.05 0.05
Number Arm16 Hrs. 24 Hrs. 16 Hrs. 24 Ers. 16 24
H rs. Hrs.
1 L 0 0 3 3 3 3
2 R 0 0 3 3 2 3
103 R 0 0 3 3 3 3
4 L 0 0 - 3 1 3 1
5 L 0 0 3 1 3 3
6 L 0 0 2 1 2 2
7 L 0 0 1 1 1 1
158 R 0 0 1 2 1 2
9 L 0 0 3 3 3 3
R 0 0 3 3 3 3
Total
Score: 0 0 25 21 24 24
Examble II: Effects of Lac-Hvdrin~ on Normal and
Corticosteroid-Treated Human Skin
Experimental Design
Note: In this example "combination" and "salt/steroid
combinaticn" refers to the use of the salt at one time
and the steroid eight hours later.
Six healthy young adult males (ages 20-34) served
as volunteers. Using procedures similar to those of
. Example I, one site of the ventral forearm received
clobetasol-17-propionate cream (0.2 ml; Temovate~,
Glaxo) daily for four weeks. Another site on the
ventral forearm received buffered ammonium lactate
(0.2 ml; 12o Lac-Hydrin~, Westwood) daily for four
weeks. A third site received a combination of Lac-
Hydrin0 in the morning (approximately 8:00 am) and
Temovate~ 8 hours later (approximately 4:00 pm), daily
for four weeks. At the end of the four week treatment
period, one 3 mm punch biopsy was obtained under lccal
anesthesia from each of the treatment sites.
-16-
WW-0049
Untreated control biopsies were also secured at
the end of four weeks.
Light Microscobv
Each 3-mm punch biopsy was fixed in 10% formalin
and processed for conventional paraffin section
histology.
Paraffin sections were stained with hematoxylin
and eosin and Hales colloidal iron for acid
mucopolysaccharides. These sections were used for
histologic and histogeometric analysis.
Histometric Analysis
For estimation of epidermal thickness, care was
taken to cut the sections perpendicularly to the
surface. Histometric measurements of the viable
epidermal area were made on both hematoxylin eosin and
Hales stained sections using computer-assisted image
analysis. Measurements were made from at least four
sections per biopsy with each section separated by
5 o u..
For estimation of ground substance, histometric
measurements were made on Hales colloidal iron-stained
sections using a Vickers M-85 microspectrophotometer.
Results
The discussion below is based cn the data
presented in Table 3.
-17-
2~~1~~~
WW-0049
Corticosteroid
All six subjects showed a marked diminution in the
viable epidermis, after 4 weeks of daily treatment
with Temovate~. Viable epidermal thickness decreases
from an average of 66,803, to 32,476 ~.2/mm of
epidermis, representing a 51% decrease in thickness.
Corticosteroid + Lac-Hydrino
All six subjects showed a diminution in viable
epidermis, after 4 weeks of daily treatment with the
combination, however, the magnitude was less.
Viable epidermis decreased from an average of
66,803, to 42,821 ~2/mm of epidermis, representing a
35% decrease in thickness. When compared with
Temovate~, the combination of Lac-Hydrin~ and
Temovate~ resulted in a 16% thicker viable epidermis,
which was significant at the 0.05 level.
Lac-Hydrino
Five of the six subjects showed a thickening of
the viable epidermis, after 4 weeks of daily treatment
with Lac-Hydrin~. One subject (~6) showed virtually
no change and another subject (~5) was a weak
responder. Viable epidermal thickness increased from
66,803 to 78,837 ~2/ru~n of epidermis, representing a
20% increase in thickness (Table 1,2). When compared
with the control, this change was significant at the
0.01 level.
These findings indicate that Lac-Hydrin~ has a
significant sparing effect on the thinning of the
viable epidermis, when used between or after
-ls-
WW-0049
applications of one of the most, if not the most,
potent topical corticosteroids, i.e., clobetasol
propionate.
In the study, Lac-Hydrin~ alone thickened the
viable epidermis significantly. This partially
negates the atrophagenic effects of the steroid.
While not wishing to be bound by any particular
theory of operation, applicants note that an increase
in Hales stainable material in the dermis suggests
that Lac-Hydrino may stimulate fibroblasts to produce
more ground substance (glycosaminoglycans). It is
well known that inhibition of fibroblast synthetic
activity, resulting in a decrease in ground substance,
is one of the major effects of topical
corticosteroids. Thus, Lac-Hydrin~ may also negate
the inhibitory effects of steroids on the fibroblast.
-19-
WW-009
Table 3: CHANGE IN THICKNESS O= VIABLE EPIDEP,~:IS TREATMENT
WITH STEROID, SrLT AND SALT/STEROID CO'"BINATION
E?IDEr't.'~L?L * $ CHANGE
THICKNESS
Salt/ Salt/
SubiectControl Steroid Salt SteroidSteroidSalt
Steroid
1 58496 25770 35535 80503 -56 -39 38
2 62506 29345 39532 93657 -53 -37 50
3 69735 31814 41397 77813 -54 -41 12
4 73033. 46750 57427 82743 -36 -21 13
5 83400 34477 42700 84834 -58 -48 2
6 53645 26705 40337 53469 -50 -25 0
* Va lues sq. microns/mm of
are epidermis
** lues elta percent ations.Negative
Va represent calcul
the
d
valuesindicatepercentagedecreases;positivevalues indicate
percentage
increases.
Example III: Study of the Effect of Ammonium Lactate on
the Effectiveness of Steroid treatment of Rhus Dermatitis
(Poison Ivy)
This is a study of topical anti-inflammatory activity
conducted in 12 healthy volunteer subjects of both sexes.
All 12 were enrolled after they had developed reactions
in four sites to topically applied Rhus extract antigen.
The four test sites {2 on each forearm) were treated
daily with measured amounts ( 20uL) of the following (1)
Lac-Hydrin~ 12% lotion; (2) Temovatem (clobetasol
propionate) 0.05% cream; (3) the combination of Temovate~
and Lac-Hydrin~, applied in the a.m. and the p.m.,
respectively, and (4) Petrolatum U.S.P. (control). After
applying the treatments to designated sites, the sites
were covered with band-aids. Treatments were applied
once daily for 5 consecutive days (Monday to Friday) a7d
the sites evaluated visually far edema, erythema,
vesiculation etc. on Friday p.m. by a dermatologist.
Efficacy is measured by the degree of resolution of
the dermatitis compared to a treated control site.
-20-
WW-0049
Test Materials
The test materials were supplied by the investigator
and were labelled alphabetically as A, B or C. The four
test sites were assigned either treatment A, treatment B,
A + B (or B + A) and Treatment C. The treatment codes
were as follows:
A = Lac-Hydrin~ (ammonium lactate)
12% lotion; lot #57B161 (Expiration 10/92)
Westwood Pharmaceuticals, Inc., Buffalo, NY 14213
(USA)
applied at a.m. visit
B = Temovate~ (clobetasol propionate) cream 0.05%
lot #Z7740DA (Expiration 05/92) Glaxo Dermatology
Products, Glaxo, Inc., Research Triangle Park, NC
27709 (USA) applied at p.m. visit
A + B - Lac Hydrin~ 12% lotion applied at a.m. visit
and Temovatem cream 0.05% applied at p.m. visit
B + A - Temovate0 cream 0.05% applied at a.m. visit and
Lac-Hydrinm 12% lotion applied at p.m. visit
C = Vaseline~ white petrolatum, USP, lot #938-C
Chesebrough-Pond's, Inc., Greenwich, CT 06830
. (USA) applied at a.m. visit
Study Groun
Rhus-antigen extract (Hollister-Stier Laboratories)
was applied as described below to designated sites on
both forearms to 19 volunteers with a strong positive
history of poison-ivy dermatitis. Of these, 12 developed
an acute vesicular dermatitis of equal intensity in all
four sites. In the remaining 7, the reactions were
either too weak or unequal in intensity and they were
dropped from the study. The 12 subjects with equal
responses were then allowed to remain in the study and
received the treatment schedules as outlined below.
-21-
~~~~1
,_ WW-0049
Procedure
After washing the forearms with a bland soap (Ivory)
and patting dry with a soft towel, four circular sites
were outlined (two on the volar aspect of each forearm)
with ink. The dermatitis was induced by the application
of 10 microliters of 1:50 dilution of poison oak-poison
ivy oleoresin (Hollister-Stier Laboratories) to a 0.6cm
disc of filter paper. The filter paper disc was then
applied to the skin and taped with impermeable plastic
tape (Blenderm, 3Mo). The Blenderm was further secured
with a non-woven surgical tape (Scanpor). This patch was
left in place for six (6) hours. At the end of six
hours, the.patch was removed and the area washed with
soap and water and then dried.
The induction patches were applied on Friday,
November 9, 1990. The volunteers returned to the
laboratory on Monday, November 12 in the morning, at
which time the test sites were examined and graded. Only
individuals with equal responses (dermatitis) in all fcur
sites were allowed to continue in the study.
Treatment Plan
Each site received about 20uL of A, B, A + B or C as
described under "materials". Test product applications
were randomized according to a randomization schedule
prepared by the investigator (Appendix B). The test
products were gently rubbed into the sites using clean
glass rods and the sites were then covered by a band-aid
to prevent rubbing against clothing, etc. In six
volunteers (fil, ~2, ~3, ~4, ~5 and ;11), Lac-HydrinQ was
applied first (in the a.m.) followed by Temovate~ in the
p.m., while in the remaining six volunteers, (~6, ~7, ~3,
9, ;10 and X12) the sequence of applications were
-22-
2~31~r
WW-0049
reversed viz. Tei~ovate~ was applied in the a.m. and Lac-
Hydrin~ in the p.m. The remaining three test sites
received either Lac-Hydrin~ alone (A) in the a.m.,
Temovate~ alone in the p.m. or Vaseline in the a.m.
Treatments were continued for 5 consecutive days. On
the last day, the sites were visually graded by the
investigator who was unaware of product assignment and
who did not participate in product application or
treatment. The forearms were also photographed after
they were graded.
Gradina Scale
The following scale was used to grade all Rhus-
induced dermatitis:
0 = complete clearing
1 = minimally elevated or palpable border with faint
erythema
2 = more elevated lesion with diffuse edema or
palpable infiltration and moderate erythema
3 = uniformly raised lesions with intense edema,
erythema and scaling or crusting
.4 = marked edema, intense erythema and vesiculation
Adverse Reactions
Patients were instructed by the investigator to
report immediately the occurrence of any adverse
experience. The adverse reaction(s), if any, were
recorded and described in detail (nature and intensity).
Dates of occurrence of any such reaction were noted,
along with dates of the details concerning any necessary
discontinuation or interruption of therapy. Any adverse
-23-
WW-0049
reaction would have been reported immediately to the
sponsor by telephone and in writing within five days.
Results
Of the 19 original volunteers, only the 12 volunteers
listed in Table 1 qualified for continuation in the study
and completed the investigation as outlined. There were
no adverse reactions or unexpected side-effects of any
kind.
The reaction scores recorded at the outset of the
study before treatments were started are listed in Table
4. The mean score (~ S.D.) for each test site was 3.4 +
0.5. The scores recorded on the last day of treatment
are displayed in Table 5.
-24-
~6~2~
WW-0049
TABLE 4
GRP.DES - DAY O, by Treatment
Vaseline
white
Subject Lac-Hydrin~ Temovate~ Lac-hydrin Petrolatum
Number 12$ Lotion Cream 0.05$ & Te~ovate (U.S.P.)
O1 4 4 4 4
02 3 3 3 3
03 4 4 4 4
04 3 3 3 3
05 3 3 3 3
06 4 4 4 4
07 4 4 4 4
OS 3 3 3 3
09 3 3 3 3
10 3 3 3 3
11 4 4 4 4
12 3 3 3 3
2 0 Mean (X) 3.4 3.4 3.4 3.4
S.D. 0.5 0.5 0.5 0.5
-25-
~~3xz'
. - WW-0049
TA3LE 5 '
GRADES - DAY 4, by Treats,ent
Vaseline
White
Subject Lac-Hydrin~ Temovate~ Lac-Hydrin~ Petrolatum
Number 12$ Lotion Cream 0.5$ & Temovate~ (U.S.P.)
O1 4 2 2 4
02 ~ 3 1 1 3
03 4 2 1 4
04 3 1 1 3
05 1 1 1 2
06 ~ 2 0 0 2
07 4 3 2 4
08 3 1 1 3
09 2 0 0 2
10 3 2 2 3
11 4 1 1 4
2 12 1 1 2 1
0
Mean (X) 2.8 1.3 1.2 2.9
S.D. 1.1 0.9 0.7 1.0
There was no major difference In the mean reaction
score following treatment by Lac-Hydrin~ compared to
Petrolatum U.S.P. (mean scores of 2.8 and 2.9
respectively). Nor were there any discernible
differences between sites treated with Temovate~ and with
Temovate~ plus Lac-Hydrin~, regardless of the sequence or
order of application.
The results confirmed that Lac-Hydrin~ had no
noticeable effect above that of Petrolatum and did not
influence the anti-inflammatory activity of Temovate~.
Temovate~ alone or with Lac-Hydrin~ produced a highly
significant (P=0.0001) effect in terms of enhancing the
resolution of the dermatitis compared to treatment with
Petrolatum alone or Lac-Hydrin~ alone.
-26-
' ~ ~~~.~~ r
h'W-0049
Discussion
There is little doubt that the use of Lac-Hydrin~
after the use of corticosteroids results in a sparing of
the viable epidermis. Examples I and III indicates that
this sparing effect was not due to either dilution of the
steroid or diminution of its efficacy.
The data generated for Lac-Hydrin~ on normal skin
(Example II) suggests that this product may behave like a
retinoid with respect to changes in the morphology of the
epidermis and dermis (thickens the epidermis, increases
ground substance). While th:~ Lac-Hydrin~ effects do not
appear to be as profound as those of the retinoids,
significant changes are achieved without any clinical
signs of irritation. This is a major advantage over
retinoid therapy for such conditions as aging skin.
It is contemplated, then, that long-term use of
topical Lac-Hydrin~ could reverse some of the changes
that normally occur to aged skin (thinning of the
epidermis and dermis), with much less irritation than is
generally caused by retinoids.
Reasonable variations, such as those which would
occur to a skilled artisan, can be made herein without
departing from the scope of the invention.
~ 25
-27-
